Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index; 35 of the 52 sources its claims cite were checked for support.

Revisiting the SSRI vs. placebo debate in the treatment of social anxiety disorder: the role of expectancy effects, neural responsivity, and monoamine transporters

Open access
Furmark, Tomas, Wahlstedt, Kurt, Faria, Vanda · 2025 · Frontiers in Psychology

Abstract

Selective serotonin reuptake inhibitors (SSRIs), widely used for anxiety and depression, are often criticized for their perceived similarity in efficacy to placebo treatments... Findings suggest shared neural pathways between SSRIs and placebos, possibly related to response expectancies.

Overview

CoChat Summary

## TL;DR

This perspective paper reviews the authors’ PET neuroimaging studies in social anxiety disorder (SAD) and argues that SSRI benefits are only partly pharmacological: expectancy effects, especially via dopamine signaling, account for much of the observed improvement. Across studies, SSRI and placebo responses shared some amygdala-related neural changes, but serotonin transporter occupancy alone did not track symptom improvement.

## Key findings

  • In 72 SAD patients from three randomized, double-blind, placebo-controlled trials, both SSRI and placebo responders showed attenuation of anxiety-related amygdala activity in the left basolateral and right ventrolateral subregions, with no significant difference between SSRI and placebo responders; clinical improvement was comparable.
  • In the deception study, overt escitalopram produced greater symptom improvement than covert escitalopram: the overt group had about twice the effect size (Cohen’s d = 2.24 vs. 1.13), and 50% vs. 14% showed clinically significant improvement; PET findings linked expectancy to dopamine transporter changes (p < 0.001, R = −0.61).
  • In the serotonin-transporter PET analysis, average serotonin transporter occupancy was 78%, but occupancy did not correlate with social anxiety improvement, and symptom improvement did not correlate with escitalopram or metabolite blood concentrations.
  • In the CBT combination study, escitalopram + CBT and placebo + CBT both improved symptoms, with LSAS-SR reductions of 37 and 24 points, respectively; longer-term outcomes at 15 months favored escitalopram + CBT (p = 0.03, Cohen’s d = 1.58 vs. 0.87).

## Methods

  • Perspective/review paper synthesizing multiple neuroimaging studies by the authors in SAD; the paper explicitly says all studies are in the public domain and there are no secondary analyses.
  • Studies discussed included PET imaging of amygdala activity, serotonin transporter binding, and dopamine transporter binding in SAD patients under SSRI, placebo, deception, and CBT conditions.
  • Main analyses compared symptom outcomes and PET-derived neurochemical/neural changes across treatment groups, including randomized double-blind placebo-controlled trials and a deception design manipulating treatment expectations.

## Limitations

  • The authors note that the deception study used only two of the four balanced-placebo conditions, because ethical and practical considerations prevented inclusion of the full design.
  • They state that the CBT study was not designed to isolate CBT’s specific effects, and expectations were not manipulated in that study.
  • Evident from the text: several conclusions come from a perspective paper summarizing prior studies rather than from one new primary dataset, and some findings are based on subsamples (for example, 27 PET participants and 24 completers in the CBT/PET study).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fpsyg.2025.1531725

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 The top panel displays changes in amygdala activity, measured by PET and regional cerebral blood flow, during an anxiety-provoking public speaking task in both responders and non-responders to SSRI and placebo treatment for social anxiety. The lower panel presents corresponding behavioral outcomes, with reduced social anxiety measured by the Liebowitz Social Anxiety Scale (LSAS) as a function of treatment. Both SSRI and placebo responders exhibited common reductions in amygdala activity and social anxiety, clearly distinguishing them from the non-responder subgroups at both the brain and behavioral levels. See Faria et al. (2012) for details.
Figure 1 The top panel displays changes in amygdala activity, measured by PET and regional cerebral blood flow, during an anxiety-provoking public speaking task in both responders and non-responders to SSRI and placebo treatment for social anxiety. The lower panel presents corresponding behavioral outcomes, with reduced social anxiety measured by the Liebowitz Social Anxiety Scale (LSAS) as a function of treatment. Both SSRI and placebo responders exhibited common reductions in amygdala activity and social anxiety, clearly distinguishing them from the non-responder subgroups at both the brain and behavioral levels. See Faria et al. (2012) for details.CC BY · PubMed Central
Figure 2 (a) PET scans of serotonin transporters in patients with social anxiety disorder, using the tracer [11C]-DASB, before treatment (left) and treatment effects (right). After treatment, an equally high average occupancy of serotonin transporters (altered binding) was observed with overt and covert SSRI treatment. No group differences were present before treatment. See Hjorth et al. (2021) for details. (b) Corresponding PET scans of dopamine transporters, using the tracer [11C]-PE2I, before treatment (left) and treatment effects in the putamen/pallidum (right). After treatment, a decrease in dopamine transporter availability was observed in the overt SSRI group, while increases were seen in the covert SSRI group. No group differences were present before treatment. See Hjorth et al. (2021) for details. (c) Percentage of responders and symptom improvement during treatment in the two groups as measured with the Liebowitz Social anxiety scale self-report (LSAS-SR) in the whole sample. See Faria et al. (2017) for details; *p < 0.05, **p < 0.01, ***p < 0.005.
Figure 2 (a) PET scans of serotonin transporters in patients with social anxiety disorder, using the tracer [11C]-DASB, before treatment (left) and treatment effects (right). After treatment, an equally high average occupancy of serotonin transporters (altered binding) was observed with overt and covert SSRI treatment. No group differences were present before treatment. See Hjorth et al. (2021) for details. (b) Corresponding PET scans of dopamine transporters, using the tracer [11C]-PE2I, before treatment (left) and treatment effects in the putamen/pallidum (right). After treatment, a decrease in dopamine transporter availability was observed in the overt SSRI group, while increases were seen in the covert SSRI group. No group differences were present before treatment. See Hjorth et al. (2021) for details. (c) Percentage of responders and symptom improvement during treatment in the two groups as measured with the Liebowitz Social anxiety scale self-report (LSAS-SR) in the whole sample. See Faria et al. (2017) for details; *p < 0.05, **p < 0.01, ***p < 0.005.CC BY · PubMed Central

Verification

Claims the paper makes

28 Valid · 3 Not valid · 9 Not checked · 24 Own results and interpretations

29 more claims · 11 with their cited sources checked

Create a free account to see all 64 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 25
  • Probably not a substantial claim. 8

Create a free account to see these claims.

Citations

Cites

Show all 52 references

Metadata

Authors
Furmark, T., Wahlstedt, K., & Faria, V.
Affiliations
Uppsala University (SE)
Corresponding author
Furmark, Tomas
Venue
Frontiers in Psychology
Published
2025-05-12
Volume
16
Pages
1531725-1531725
ISSN
1664-1078 (ISSN-L)
OpenAlex
W4410282128
Cited by
1
References
52
Citations by year
2026: 1
FWCI
1.05
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Psychology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Uppsala University Publications (Uppsala University) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Vetenskapsrådet
  • Riksbankens Jubileumsfond
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
selective serotonin reuptake inhibitors, social anxiety disorder, placebo effect, expectancy effects, amygdala activity, dopamine signaling, serotonin transporter, monoamine transporters, cognitive behavioral therapy, fear processing, serotonin reuptake inhibition, treatment response

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Revisiting the SSRI vs. placebo debate in the treatment of social anxiety disorder: the role of expectancy effects, neural responsivity, and monoamine transporters. https://app.cochat.ai/papers/10.3389/fpsyg.2025.1531725
The paper
Furmark, T., Wahlstedt, K., & Faria, V. (2025). Revisiting the SSRI vs. placebo debate in the treatment of social anxiety disorder: the role of expectancy effects, neural responsivity, and monoamine transporters. Frontiers in Psychology. https://doi.org/10.3389/fpsyg.2025.1531725

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.